News

Velcura earlier completed a successful Phase Ia clinical trial of VEL-0230 in healthy individuals. Importantly, a rapid and significant reduction in bone resorption was observed in individuals treated

Mr Vazquez, who earned his bachelor of arts degree in biology and JD from the University of Puerto Rico, has assembled an experienced team of sales representatives and

CardioFit is intended as a treatment for New York Heart Association class II-III heart failure patients who have failed to achieve symptomatic improvement through standard evidence based management.

Participating in the financing were existing investors Claremont Creek Ventures and Sequoia Capital as well as new investor Alafi Capital. Matthew Rabinowitz, president and CEO of Gene Security

“I am pleased Howard has joined our R&D organization as we look to further build our robust pipeline in areas of significant unmet medical need in neuroscience,” said

This approval will enable a Phase Ib study of triphendiol in combination with gemcitabine in patients with unresectable, locally advanced or metastatic pancreatic and bile duct cancers. Triphendiol

Prior to Auspex, Mr Grey was president and CEO of SGX Pharmaceuticals, which was recently acquired by Eli Lilly. Prior to joining SGX, Mr Grey was president and

Stuart Randle, CEO of GI Dynamics, said: “We are very pleased to announce that we have received both the ISO certification and the CE mark approval, which are

According to the company, an application for sales approval will be submitted shortly and the sales of the product will begin at the end of the second quarter